

Supplementary Material

Table S1: Cation-dependency: MIC gentamicin [$\mu\text{g/ml}$] of GAR in different media.





Strain: *E. coli* C600Z1, induction: 250 ng/ml anhydrotetracycline. Median of two – four biological replicates.





	Induced	Increase of MIC	Not induced	Increase of MIC
LB plates, E-test				
pZE21- <i>gar</i>	128	171	0.625	2
pZE21-MCS1	0.75		0.345	
MH plates, E-test				
pZE21- <i>gar</i>	64	1000	0.157	2
pZE21-MCS1	0.064		0.064	
LB broth, BMD				
pZE21- <i>gar</i>	5.76	3	4.32	2
pZE21-MCS1	2.16		2.16	
MH broth, BMD				
pZE21- <i>gar</i>	184	657	0.4	2
pZE21-MCS1	0.28		0.2	
Cation-adjusted MH broth, BMD				
pZE21- <i>gar</i>	121	2017	0.1	2
pZE21-MCS1	0.06		0.05	





In order to further confirm and quantify the level of gentamicin resistance conferred by GAR, we determined MIC values by standard broth microdilution in LB medium (Table S1). Here, MIC values were raised only by factor 3. It was shown earlier that divalent cations increase aminoglycoside MIC values [1, 2]. Consequently, the addition of agar in the first test, containing an unknown amount of cations, resulted in increased resistance. A hypothesis behind this phenomenon is that mono- and divalent cations, especially Mg^{2+} and Ca^{2+} , antagonize the antibiotic effect most likely by displacement of the aminoglycoside from a site at the cell wall thereby stopping uptake, as shown for both Gram-negative and Gram-positive bacteria [3, 4]. We then performed broth microdilution (BMD) in MH broth and E-test on MH plates, which both led to a more than 600x increase of the MIC. The highest resistance level was measured in the medium with the highest cation concentration, cation-adjusted MH broth (20-25 mg Ca^{2+}/L and 10-12.5 mg Mg^{2+}/L , equalling about 500 μM of each) [5]. However, this increase in MIC could not be found in the negative controls without resistance gene suggesting that this is not the complete explanation. The observation that the MIC was only changed in a cation-dependent fashion for strains expressing *gar* indicates a more direct interaction. GAR contains an AAA domain and shares similarities with nucleotide and gluconate kinases (Fig. 2, main article). These, the known aminoglycoside nucleotidyltransferases and aminoglycoside phosphotransferases as well as other P-loop containing NTPases are Mg^{2+} -dependent enzymes [6-10]. Ideally, the concentration of free Mg^{2+} in the cytosol is kept stable between 1 – 5 mM and, additionally, a large amount of Mg^{2+} is bound and required by the ribosomes [11]. Intracellular free Mg^{2+} can vary between 1 μM and 10 mM depending on the extracellular concentration [12]. The concentration of divalent cations in cation-adjusted MH medium is sufficient for all cellular functions but requires active enrichment of Mg^{2+} in the cells. We cannot exclude that extremely low concentrations in the medium might cause lower levels of free Mg^{2+} in the cytosol and lead to the observed decrease in resistance by limiting GAR activity, although this remains to be shown.

Since cation concentrations influenced MIC values profoundly, we decided to perform all subsequent experiments in cation-adjusted MH broth. In order to reliably compare GAR activity against a broad palette of aminoglycosides, we additionally chose to change vector and bacterial strain. The vector pZE21 includes an APH(3') kanamycin resistance (although not active against gentamicin) and thus all mentioned MIC determinations were performed in presence of 50 µg/ml kanamycin. The strain *E. coli* C600Z1 also harbours a chromosomal spectinomycin resistance determinant, making it less suitable. We therefore cloned the ORF *gar* into pUC19 replacing the ampicillin resistance gene. The plasmid pUC19-*gar* was then transformed into *E. coli* BL21(DE3), which contains no internal resistance gene and requires no induction of *gar* expression. The resulting strain showed a 2760x gentamicin MIC increase in cation-adjusted MH (Fig. 1, main article).

Table S2: Chemical structure of the tested aminoglycosides and resistance profile conveyed by GAR. Suspected target garosamine is marked. Chemical structures were prepared using ACD/ChemSketch (Freeware) 2018.1.1.

Antibiotic	Structure	Manufacturer and catalog number	MIC increase (fold-change)
Netilmicin		Sigma 1460500 USP	5140
G418		Sigma G1279	4850
Isepamicin		TOKU-E I042	4110
Sisomicin		Sigma 1612801 USP	3430

Antibiotic	Structure	Manufacturer and catalog number	MIC increase (fold-change)
Micronomicin	 <p>The structure shows a 2-deoxystreptamine core with a methylamino group (H₃C-NH) and a methyl group (H₃C) on the C2' position, which are circled in red. The core is linked via glycosidic bonds to two 2-deoxy-2-amino-3,6-diaminocyclohexane rings. The second ring has a methylaminoethyl side chain (-CH₂-NH-CH₃).</p>	TOKU-E M018	3080
Gentamicin	 <p>The structure is similar to Micronomicin but with a variable R group on the second cyclohexane ring. The C2' position of the 2-deoxystreptamine core is circled in red.</p> <p>R = C1 - CH₂NH₂, C2 - C₂NH₆, or C3 - C₃NH₈</p>	Sigma G3632	2760
Tobramycin	 <p>The structure shows a 2-deoxystreptamine core with a hydroxyl group (HO) at C2' and a hydroxymethyl group (-CH₂-OH) at C3'. It is linked to two 2-deoxy-2-amino-3,6-diaminocyclohexane rings, one of which has a primary aminoethyl side chain (-CH₂-NH₂).</p>	Sigma T4014	16
Kanamycin	 <p>The structure shows a 2-deoxystreptamine core with a hydroxyl group (HO) at C2' and a hydroxymethyl group (-CH₂-OH) at C3'. It is linked to two 2-deoxy-2-amino-3,6-diaminocyclohexane rings, one of which has a primary aminoethyl side chain (-CH₂-NH₂). The second ring has a variable R₁ group and a variable R group.</p> <p>R/R₁ = NH₂ or OH</p>	Sigma K4000	8

Antibiotic	Structure	Manufacturer and catalog number	MIC increase (fold-change)
Amikacin	 <p>The structure of Amikacin is a complex aminoglycoside consisting of three linked rings: a 2-deoxystreptamine core, a 2-deoxyadenosine ring, and a 2-deoxystreptamine ring. It features multiple hydroxyl groups, amino groups, and a side chain with a primary amine and a hydroxyl group.</p>	Sigma A3650	8
Paromomycin	 <p>The structure of Paromomycin is a complex aminoglycoside consisting of three linked rings: a 2-deoxystreptamine core, a 2-deoxyadenosine ring, and a 2-deoxystreptamine ring. It features multiple hydroxyl groups, amino groups, and a side chain with a primary amine and a hydroxyl group.</p>	Sigma P5057	8
Ribostamycin	 <p>The structure of Ribostamycin is a complex aminoglycoside consisting of three linked rings: a 2-deoxystreptamine core, a 2-deoxyadenosine ring, and a 2-deoxystreptamine ring. It features multiple hydroxyl groups, amino groups, and a side chain with a primary amine and a hydroxyl group.</p>	Sigma R2255	4
Apramycin	 <p>The structure of Apramycin is a complex aminoglycoside consisting of three linked rings: a 2-deoxystreptamine core, a 2-deoxyadenosine ring, and a 2-deoxystreptamine ring. It features multiple hydroxyl groups, amino groups, and a side chain with a primary amine and a hydroxyl group.</p>	Sigma A2024	4




Antibiotic	Structure	Manufacturer and catalog number	MIC increase (fold-change)
Hygromycin B		Sigma H3274	3
Streptomycin		Sigma S6501	2
Spectinomycin		Sigma S4014	1

Table S3: Predicted and determined resistances of *Pseudomonas aeruginosa* 105MG.

This isolate (sequenced in this study) contains five aminoglycoside resistance genes including *gar*. It is also resistant against cabapenems, cephalosporins, penicillins and fluoroquinolones [13] and harbours resistance genes against chloramphenicol, fosfomicin, sulfonamides, trimethoprim and tetracycline.

	<i>aph(3)-IIb</i>	<i>aac(6)-31</i>	<i>aadA6</i>	<i>aac(6)-II</i>	<i>gar</i>	Determined resistance
Kanamycin	X	X	-	X	-	X
Gentamicin	-	X	-	X	X	X
Netilmicin	-	X	-	X	X	X
Sisomicin	-	X	-	X	X	X
G418	X	-	-	-	X	X
Micronomicin	-	-	-	-	X	X
Isepamicin	X	X	-	X	X	X
Amikacin	X	X	-	X	-	X
Tobramycin	-	X	-	X	-	X
Paromomycin	X	-	-	-	-	X
Ribostamycin	X	X	-	X	-	X
Hygromycin B	?	?	-	?	-	X
Apramycin	?	?	-	?	-	-
Spectinomycin	?	-	X	-	-	X
Streptomycin	?	-	X	-	-	X

Resistance profiles of the listed aminoglycoside modifying enzymes: [14] and references therein.

Table S4: Predicted resistances of *Luteimonas* sp. 83-4.

This isolate (complete genome, accession CP029556.1) contains two aminoglycoside resistance genes including *gar*.

	<i>aph(3')-XV</i>	<i>gar</i>
Kanamycin	X	-
Gentamicin	-	X
Netilmicin	-	X
Sisomicin	-	X
G418	X	X
Micronomicin	-	X
Isepamicin	X	X
Amikacin	X	-
Tobramycin	-	-
Paromomycin	X	-
Ribostamycin	X	-
Hygromycin B	?	-
Apramycin	?	-
Spectinomycin	?	-
Streptomycin	X	-

Table S5: Occurrence of *gar* in 1251 metagenomic datasets.

The number of paired-end reads mapping to *gar* with 100 % identity over the length of at least 20 amino acids are shown. Reads from selected metagenomic datasets (ERR1713392, ERR1713378) were mapped to DNA sequences containing *gar* and surrounding attachment sites. Paired-end reads covered *gar* and the adjacent attachment site unambiguously, confirming that *gar* is present as a gene cassette in both metagenomes.

Metagenome	Raw count	Environment	Country	Latitude	Longitude
ERR1713392	15	Wastewater/sludge	Sweden	57.7089	11.9746
ERR1713378	13	Wastewater/sludge	Nigeria	7.3775	3.9470
ERR1726005	7	Wastewater/sludge	Sweden	57.7089	11.9746
ERR1726006	6	Wastewater/sludge	Sweden	57.7089	11.9746
ERR1725942	5	Wastewater/sludge	Australia	-37.9145	144.6432
ERR1414237	4	Wastewater/sludge	Sweden	59.3107	18.1084
ERR1725996	4	Wastewater/sludge	Nigeria	7.3775	3.9470
ERR1713407	3	Wastewater/sludge	Viet Nam	10.8231	106.6297
104	2	Sediment	India	18.5104	73.8399
ERR2592328	2	Wastewater/sludge	Australia	-35.3452	149.0950
ERR1713369	2	Wastewater/sludge	Kenya	1.2921	36.8219
ERR1414243	1	Wastewater/sludge	Sweden	59.3556	18.2271
ERR1414272	1	Wastewater/sludge	Sweden	59.3556	18.2271
111	1	Wastewater/sludge	India	19.0760	72.8777
ERR1713332	1	Wastewater/sludge	Australia	-35.3452	149.0950
ERR1713333	1	Wastewater/sludge	Australia	-37.9145	144.6432
ERR1713372	1	Wastewater/sludge	Luxembourg	49.5096	5.9221

Table S6: Composition of the 1251 metagenomics datasets.

See Additional file 2 for the extensive list.

Source	Nr. of metagenomes
Wastewater/sludge	453
Human, individuals	339
Marine environments	203
Hydrothermal vent	143
River/lake sediment	46
Estuary	19
River/lake sediment, pharmaceutical impact	16
Soil	16
Thermophilic anaerobic methanogenic reactor	5
Cold seep sediment	3
Alkaline water	3
Oyster gut	2
Crater lake (stromatolite)	2
Hot spring	1

References

1. Garrod LP, Waterworth PM. Effect of medium composition on the apparent sensitivity of *Pseudomonas aeruginosa* to gentamicin. *J Clin Pathol.* 1969;22:534-8. doi: 10.1136/jcp.22.5.534.
2. D'Amato RF, Thornsberry C, Baker CN, Kirven LA. Effect of calcium and magnesium ions on the susceptibility of *Pseudomonas* species to tetracycline, gentamicin polymyxin B, and carbenicillin. *Antimicrob Agents Chemother.* 1975;7:596-600. doi: 10.1128/aac.7.5.596.
3. Bryan LE, Van Den Elzen HM. Effects of membrane-energy mutations and cations on streptomycin and gentamicin accumulation by bacteria: a model for entry of streptomycin and gentamicin in susceptible and resistant bacteria. *Antimicrob Agents Chemother.* 1977;12:163-77. doi: 10.1128/aac.12.2.163.
4. Beggs WH, Andrews FA. Inhibition of dihydrostreptomycin binding to *Mycobacterium smegmatis* by monovalent and divalent cation salts. *Antimicrob Agents Chemother.* 1976;9:393-6. doi: 10.1128/aac.9.3.393.
5. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: M07-A9; approved standard. 9. ed. Wayne, PA 19087 USA: Committee for Clinical Laboratory Standards Institute; 2012.
6. Das U, Wang LK, Smith P, Munir A, Shuman S. Structures of bacterial polynucleotide kinase in a Michaelis complex with nucleoside triphosphate (NTP)-Mg²⁺ and 5'-OH RNA and a mixed substrate-product complex with NTP-Mg²⁺ and a 5'-phosphorylated oligonucleotide. *J Bacteriol.* 2014;196:4285-92. doi: 10.1128/JB.02197-14.
7. Kraft L, Sprenger GA, Lindqvist Y. Conformational changes during the catalytic cycle of gluconate kinase as revealed by X-ray crystallography. *J Mol Biol.* 2002;318:1057-69. doi: 10.1016/S0022-2836(02)00215-2.
8. Cox G, Stogios PJ, Savchenko A, Wright GD. Structural and molecular basis for resistance to aminoglycoside antibiotics by the adenylyltransferase ANT(2'')-Ia. *MBio.* 2015;6. doi: 10.1128/mBio.02180-14.
9. Labby KJ, Garneau-Tsodikova S. Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections. *Future Med Chem.* 2013;5:1285-309. doi: 10.4155/fmc.13.80.
10. Miller JM, Enemark EJ. Fundamental Characteristics of AAA+ Protein Family Structure and Function. *Archaea.* 2016;2016:9294307. doi: 10.1155/2016/9294307.
11. Nierhaus KH. Mg²⁺, K⁺, and the ribosome. *J Bacteriol.* 2014;196:3817-9. doi: 10.1128/JB.02297-14.
12. Hurwitz C, Rosano CL. The intracellular concentration of bound and unbound magnesium ions in *Escherichia coli*. *J Biol Chem.* 1967;242:3719-22. <http://www.ncbi.nlm.nih.gov/pubmed/5341484>.
13. Giske CG, Libisch B, Colinon C, Scoulica E, Pagani L, Fūzi M, et al. Establishing clonal relationships between VIM-1-like metallo-beta-lactamase-producing *Pseudomonas aeruginosa* strains from four European countries by multilocus sequence typing. *J Clin Microbiol.* 2006;44:4309-15. doi: 10.1128/JCM.00817-06.
14. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. *Drug Resist Updat.* 2010;13:151-71. doi: 10.1016/j.drup.2010.08.003.